Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

EDMUND SCOTT KOPETZ

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1205920048
CMS profile
236273
Location
HOUSTON, TX

General Payments · PY2018–2024

$269,256.72

  • Reported across 184 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$49,238.38

33 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $47,069.00 16
Travel and Lodging $1,534.67 5
Food and Beverage $634.71 12

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $16,509.49 11
ABBVIE INC. $7,462.50 5
F. Hoffmann-La Roche AG $6,080.00 2
E.R. Squibb & Sons, L.L.C. $5,352.47 5
Merck KGaA $5,325.00 1
Merck Sharp & Dohme Corporation $3,094.92 6
Acerta Pharma LLC $2,740.00 1
Janssen Scientific Affairs, LLC $2,025.00 1
Amgen Inc. $649.00 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $4,027.01 10
PY2019 $39,748.05 39
PY2020 $37,130.06 17
PY2021 $52,592.02 23
PY2022 $24,822.02 19
PY2023 $61,699.18 43
PY2024 $49,238.38 33

Payment records · PY2024 (33)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $55.00 05/31/2024 Food and Beverage Undisputed 01/23/2026 1104098244 CMS
ABBVIE INC. $45.00 05/31/2024 Food and Beverage Undisputed 01/23/2026 1104098246 CMS
ABBVIE INC. $3,987.50 10/02/2024 Consulting Fee Undisputed 01/23/2026 1103136407 CMS
ABBVIE INC. $2,700.00 10/03/2024 Consulting Fee Undisputed 01/23/2026 1103136409 CMS
ABBVIE INC. $675.00 10/03/2024 Consulting Fee Undisputed 01/23/2026 1103136411 CMS
Amgen Inc. $649.00 05/03/2024 Consulting Fee Undisputed 01/23/2026 1117601449 CMS
AstraZeneca Pharmaceuticals LP $2,740.00 06/06/2024 Consulting Fee Undisputed 01/23/2026 1105396690 CMS
E.R. Squibb & Sons, L.L.C. $325.00 05/17/2024 Consulting Fee Undisputed 01/23/2026 1101789727 CMS
E.R. Squibb & Sons, L.L.C. $2,112.50 05/22/2024 Consulting Fee Undisputed 01/23/2026 1101789723 CMS
E.R. Squibb & Sons, L.L.C. $325.00 06/24/2024 Consulting Fee Undisputed 01/23/2026 1101789753 CMS
E.R. Squibb & Sons, L.L.C. $9.97 09/13/2024 Food and Beverage Undisputed 01/23/2026 1101789894 CMS
E.R. Squibb & Sons, L.L.C. $2,580.00 12/02/2024 Consulting Fee Undisputed 01/23/2026 1101789879 CMS
F. Hoffmann-La Roche AG $4,180.00 11/05/2024 Consulting Fee Undisputed 01/23/2026 1133004595 CMS
F. Hoffmann-La Roche AG $1,900.00 11/18/2024 Consulting Fee Undisputed 01/23/2026 1133004599 CMS
GlaxoSmithKline, LLC. $61.07 03/21/2024 Food and Beverage Undisputed 01/23/2026 1116043128 CMS
GlaxoSmithKline, LLC. $53.22 03/21/2024 Food and Beverage Undisputed 01/23/2026 1116215848 CMS
GlaxoSmithKline, LLC. $20.69 03/21/2024 Food and Beverage Undisputed 01/23/2026 1116304563 CMS
GlaxoSmithKline, LLC. $110.55 03/21/2024 Food and Beverage Undisputed 01/23/2026 1116389094 CMS
GlaxoSmithKline, LLC. $78.97 03/21/2024 Food and Beverage Undisputed 01/23/2026 1116393152 CMS
GlaxoSmithKline, LLC. $68.98 03/21/2024 Food and Beverage Undisputed 01/23/2026 1116430519 CMS
GlaxoSmithKline, LLC. $728.14 03/21/2024 Travel and Lodging Undisputed 01/23/2026 1116471054 CMS
GlaxoSmithKline, LLC. $416.18 03/21/2024 Travel and Lodging Undisputed 01/23/2026 1116586055 CMS
GlaxoSmithKline, LLC. $55.14 03/21/2024 Food and Beverage Undisputed 01/23/2026 1116691663 CMS
GlaxoSmithKline, LLC. $116.55 03/21/2024 Travel and Lodging Undisputed 01/23/2026 1116708699 CMS
GlaxoSmithKline, LLC. $14,800.00 04/22/2024 Consulting Fee Undisputed 01/23/2026 1116513759 CMS
Janssen Scientific Affairs, LLC $2,025.00 06/06/2024 Consulting Fee Undisputed 01/23/2026 1078860267 CMS
Merck KGaA $5,325.00 02/08/2024 Consulting Fee Undisputed 01/23/2026 1133237975 CMS
Merck Sharp & Dohme LLC $53.20 06/04/2024 Food and Beverage Undisputed 01/23/2026 1141658358 CMS
Merck Sharp & Dohme LLC $123.80 06/04/2024 Travel and Lodging Undisputed 01/23/2026 1141658480 CMS
Merck Sharp & Dohme LLC $22.92 06/04/2024 Food and Beverage Undisputed 01/23/2026 1141855887 CMS
Merck Sharp & Dohme LLC $610.00 06/12/2024 Consulting Fee Undisputed 01/23/2026 1141578972 CMS
Merck Sharp & Dohme LLC $2,135.00 06/19/2024 Consulting Fee Undisputed 01/23/2026 1141816397 CMS
Merck Sharp & Dohme LLC $150.00 06/19/2024 Travel and Lodging Undisputed 01/23/2026 1141816399 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.